SEC-sourced researchBeta

SRPT

Sarepta Therapeutics, Inc.

US markets

Data passport

CIK: 0000873303
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 23, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 11:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

SRPT · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	1,144,876,000.0000	Mar 2, 2026
December 2024	1,787,960,000.0000	Mar 2, 2026
December 2025	1,864,296,000.0000	Mar 2, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	1,864,296,000.0000	-713,410,000.0000	-205,479,000.0000	3,349,703,000.0000	2,209,081,000.0000	Mar 2, 2026
December 2024	1,787,960,000.0000	235,239,000.0000	-205,787,000.0000	3,963,173,000.0000	2,435,431,000.0000	Mar 2, 2026
December 2023	1,144,876,000.0000	-535,977,000.0000	-500,993,000.0000	—	—	Mar 2, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$1.86B	December 2025	Mar 2, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$1.79B	December 2024	Mar 2, 2026	10-K
Net incomeNetIncomeLoss	-$713.41M	December 2025	Mar 2, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$205.48M	December 2025	Mar 2, 2026	10-K
Total assetsAssets	$3.35B	December 2025	Mar 2, 2026	10-K
Total liabilitiesLiabilities	$2.21B	December 2025	Mar 2, 2026	10-K

New filings

Explore methodology ↗